| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/18/2008 | CN101199834A Chinese medicine compound for treating lung cancer and preparing method thereof |
| 06/18/2008 | CN101199763A Capsule auxiliary for treating cancer and preparing method thereof |
| 06/18/2008 | CN101199725A Extracting technique of Lingelsh |
| 06/18/2008 | CN101199667A Chinese medicine for treating leukemia, aplastic anemia |
| 06/18/2008 | CN101199666A Anti-tumor effect of black nightshade total alkali and medicament agent |
| 06/18/2008 | CN101199621A Medicament for treating leukemia and preparing method |
| 06/18/2008 | CN101199596A Chinese medicine compound of alleviating cancer release, chemo-treatment toxicum side effect and preparing method thereof |
| 06/18/2008 | CN101199593A Salvia miltiorrhiza valid component, preparing method and application |
| 06/18/2008 | CN101199569A Medicament compound with anti-tumor function and preparing method thereof |
| 06/18/2008 | CN101199568A Medicament compound for treating cardiovascular disease and preparing method thereof |
| 06/18/2008 | CN101199563A Loosestrife total saponine anti-tumor function |
| 06/18/2008 | CN101199554A Oil-soluble propolis soft capsule and preparing method thereof |
| 06/18/2008 | CN101199550A Method of preparing containing endothelium ancestor cell preparation utilizing umbilical or placenta and uses thereof |
| 06/18/2008 | CN101199537A Hif hydroxylase inhibitors |
| 06/18/2008 | CN101199534A Anti-tumor function of raw panoxadiol derivative |
| 06/18/2008 | CN101199517A Mitozolomide controlled-release planting dose for treating entity tumor |
| 06/18/2008 | CN101199513A Method of forming indole framework compound by catalysis reaction and application in anti-cancer medicament |
| 06/18/2008 | CN101199512A Hif hydroxylase inhibitors |
| 06/18/2008 | CN101199511A Andrographis lactone self-emulsification capsule of antibacterial antiphlogistic |
| 06/18/2008 | CN101199509A Function of 2',2'-CH3-2'H,4H-3,6'-two benzopyran-4-ketone |
| 06/18/2008 | CN101199507A Application of furan diene and derivatives in preparing therapeautic cancer medicament |
| 06/18/2008 | CN101199506A Oxaliplatin lyophilized powder injection and preparing method thereof |
| 06/18/2008 | CN101199503A Hif hydroxylase inhibitors |
| 06/18/2008 | CN101199502A Hif hydroxylase inhibitors |
| 06/18/2008 | CN101199501A HIF hydroxylase inhibitors |
| 06/18/2008 | CN101199498A Medicament of anti-nipple tumor virus infection |
| 06/18/2008 | CN101199486A Ratio karoo amine slice and preparing technique thereof |
| 06/18/2008 | CN101199483A Stable anti-HER2 humanized antibody preparation |
| 06/18/2008 | CN101199344A Integrated technology of asparagus' all-nutrient substance |
| 06/18/2008 | CN100395335C siRNA double-chain for suppressing bc1-2 gene expression |
| 06/18/2008 | CN100395334C siRNA double-chain for suppressing bc1-2 gene expression |
| 06/18/2008 | CN100395259C Steroid derivatives |
| 06/18/2008 | CN100395255C Ammonia maleate rubicin salt, and its preparing method and use |
| 06/18/2008 | CN100395242C Naphthalene alkoxy and naphthaquinone kind pyrane carbonic glucoside compound and preparation process thereof |
| 06/18/2008 | CN100395241C Degradeable furan sesterterpenes keratinous spongistatin, and its preparing method and use |
| 06/18/2008 | CN100394958C Composition of medication for treating tumor, preparation method and application |
| 06/18/2008 | CN100394927C Liver cancer resistant Antrodia camphorata and preparation method thererof |
| 06/18/2008 | CN100394921C Freeze-drying powder for injecting lentinan and its content determination |
| 06/18/2008 | CN100394920C Use of 5-substituted nucleosides for reinforcing the apoptotic effect of cytostatic drugs |
| 06/18/2008 | CN100394860C Extracts of cacao bean and cacao bean husk with inhibitory effects on carcinogenesis |
| 06/18/2008 | CA2571348A1 Anti-tumour immunity and specific t cell memory are induced by low dose inoculation with nonreplicating recombinant adenovirus encoding tap1 |
| 06/17/2008 | USRE40387 7,11-dihydroxy 8,8,10,12,16-pentamethyl-3-(1-methyl-2-(2-methyl-4-thiazolyl) ethenyl-17-oxa-4-azabicyclo(14.1.0)heptadecane-5,9-dione and neutralizing buffer in an amount sufficient to reduce its decomposition; increasing the bioavailability of orally administered epothilones; anticarcinogenic agent |
| 06/17/2008 | US7388078 Nucleic acids encoding polypeptides having chips activity |
| 06/17/2008 | US7388075 Medicament containing activated antithrombin III |
| 06/17/2008 | US7388072 Melanoma Associated antigen (MAGE) tumor associated genes, nucleic acids encoding such peptides and antibodies relating thereto; Human Leukocyte Antigen (HLA) |
| 06/17/2008 | US7388071 Telomerase peptide is modified to enhance binding to a major histocompatibility complex (MHC) molecule |
| 06/17/2008 | US7388070 inhibitors of DNA polymerase and DNA repair enzymes for treating viral infections, bacterial infections, fungal infections, protozoan infections, and neoplastic diseases; herpes viruses, herpes simplex virus (HSV), and human cytomegalovirus (CMV); peptidomimetics that mimic helical portions of proteins |
| 06/17/2008 | US7388026 Antitumor antibiotic; water solubility, stability; N-[2-{(1-chloromethyl)-1,2-dihydro-5-[(4-methylpiperazino)carbonyloxy]-3H-benz(e)indol-3-yl}carbonyl]-1H-indol-5-yl]-5-[(3-methyldithio-1-oxopropyl)-amino]-1H-indole-2-carboxamide |
| 06/17/2008 | US7388015 inhibitors of cyclin-dependent kinases (CDKs); cancer, leukemia, psoriasis |
| 06/17/2008 | US7388010 fused hexacyclic derivatives consist of pyrrolidine, indazolone, quuinoxalinone rings; cyclin-dependent kinase inhibitor with cell growth-inhibitory activity; anticarcinogenic and antiproliferative agent |
| 06/17/2008 | US7388009 Heterocyclic drugs as enzyme inhibitors for Kinase enzymes or prodrugs |
| 06/17/2008 | US7388005 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo [1,2-a]pyrimidin-5(1H)one derivatives for neurodegenerative disorders |
| 06/17/2008 | US7387998 STQ peptides |
| 06/17/2008 | US7387994 Antitumor, anticancer agents; particles or coils or stents coated solid-phase agent comprising a binding agent comprising collagen are directed to target vasculature, such as the vasculature of solid tumor masses or aneurysms |
| 06/17/2008 | US7387873 Human myeloma cell line |
| 06/17/2008 | US7387791 Oral administering; tablet with enteric coating; supplying drug to gastrointestinal systems |
| 06/17/2008 | US7387790 Non-gas containing nanoparticles comprising a mixture of select lipids capable of being internalized within a targeted tissue or cell sufficient to achieve a desired effect; anticancer agents |
| 06/17/2008 | US7387777 Methods of treating hemophilia or von willebrand disease with p-selectin |
| 06/17/2008 | US7387776 Human monoclonal antibodies against CD30 |
| 06/17/2008 | US7387771 dissolving in carrier liquid; drug linked to a protein-binding molecule via a spacer which is cleaved hydrolytically or enzymatically in the body of a subject in a pH-dependent manner; tissue targeted delivery; Doxorubicin-phenylacetylhydrazone spacer-maleimide |
| 06/17/2008 | CA2439152C Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 06/17/2008 | CA2395193C Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 06/17/2008 | CA2369947C Hydroxamic acid derivative |
| 06/17/2008 | CA2367704C Pyrazolobenzodiazepines as cdk2 inhibitors |
| 06/17/2008 | CA2356380C Immunosuppressive effects of pteridine derivatives |
| 06/17/2008 | CA2331737C Agents for relieving side effects caused by use of an anti-tumour agent |
| 06/17/2008 | CA2251886C An oral pharmaceutical formulation containing ibandronate |
| 06/17/2008 | CA2249446C Irreversible inhibitors of tyrosine kinases |
| 06/17/2008 | CA2202487C Fused pyrrolocarbazoles |
| 06/17/2008 | CA2189051C Composition for delivery of toxic radioisotopes to the cell nucleus and use |
| 06/17/2008 | CA2187162C Dna encoding precursor of interleukin-1.beta. converting enzyme-related cysteine proteinase iii (icerel iii) |
| 06/17/2008 | CA2151826C Pharmaceutical compositions for prevention and treatment of cancerous diseases and process for their preparation |
| 06/12/2008 | WO2008070858A1 Inhibiting translation of abrerrant dnmt3b transcripts in cancer cells using inhibitory nucleic acids |
| 06/12/2008 | WO2008070740A1 Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| 06/12/2008 | WO2008070350A2 Methods and compositions related to wrapping of dehydrons |
| 06/12/2008 | WO2008070136A1 Compositions including triciribine and one or more platinum compounds and methods of use thereof |
| 06/12/2008 | WO2008070100A1 Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
| 06/12/2008 | WO2008070090A2 Compositions and methods for diagnosing and treating cancer |
| 06/12/2008 | WO2008070047A2 Immunogens in cancer stem cells |
| 06/12/2008 | WO2008070011A2 Combination of an hdac inhibitor and an antimetabolite |
| 06/12/2008 | WO2008070009A2 Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes |
| 06/12/2008 | WO2008069922A1 Compositions including triciribine and anthracyclin analogs and methods of use thereof |
| 06/12/2008 | WO2008069276A1 Cancer therapeutic agent and anti-carcinogenic agent |
| 06/12/2008 | WO2008069168A1 Method for production of 2-hydroxymethylpyrrolidin-3,4-diol or intermediate thereof |
| 06/12/2008 | WO2008068751A1 Novel protein kinase modulators and therapeutic uses thereof |
| 06/12/2008 | WO2008068516A1 Chelating agent |
| 06/12/2008 | WO2008068507A2 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment |
| 06/12/2008 | WO2008068171A1 Substituted pyrimidines and their use as jnk modulators |
| 06/12/2008 | WO2008068170A1 Hdac inhibitors |
| 06/12/2008 | WO2008067892A1 Sulphamate benzothiophene derivatives |
| 06/12/2008 | WO2008067756A1 3-pyrrolo-cyclohexylene-2-dihydro-indolinone derivatives and uses thereof |
| 06/12/2008 | WO2008052030A3 A method for increasing antibody-dependent cytotoxicity with castanospermine |
| 06/12/2008 | WO2008047134A3 Antibody molecules which bind il-17a and il-17f |
| 06/12/2008 | WO2008026223A3 An aqueous formulation for selective targeting and delivering gene to cancer cells |
| 06/12/2008 | WO2008025964A3 Antibodies to an epitope of agr2. assays and hybridomas |
| 06/12/2008 | WO2008020596A3 Treating or preventing cancers over-expressing reg4 or kiaa0101 |
| 06/12/2008 | WO2008003514A3 Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy |
| 06/12/2008 | WO2007144709A3 Leptomycin derivatives |
| 06/12/2008 | WO2007143098A3 Hepatocyte growth factor (hgf) binding proteins |
| 06/12/2008 | WO2007128537A3 Pharmaceutical preparation based on myrtucommulone a for the selective tumour and cancer therapy |